Disease Detail

ID DOID:80188
Name chronic myelomonocytic leukemia
Definition A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of anatomical entity hematopoietic system disease hematologic cancer leukemia chronic leukemia chronic myelomonocytic leukemia
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia chronic leukemia chronic myelomonocytic leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown TG101209 chronic myelomonocytic leukemia not applicable detail...
Unknown unknown H3B-8800 chronic myelomonocytic leukemia not applicable detail...
SETBP1 mutant N/A chronic myelomonocytic leukemia not applicable detail...
ASXL1 mutant N/A chronic myelomonocytic leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Active, not recruiting
NCT02546284 Phase I LAM-003 Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) Recruiting
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Recruiting
NCT02841540 Phase I H3B-8800 Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Recruiting
NCT03268954 Phase III Azacitidine + MLN4924 Azacitidine Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) Recruiting
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Recruiting
NCT03358719 Phase I DEC-205-NY-ESO-1 + Decitabine + Nivolumab + Poly ICLC DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Recruiting
NCT03383575 Phase II Azacitidine + Enasidenib Enasidenib Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome Recruiting
NCT03386513 Phase I IMGN632 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Recruiting
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Recruiting
NCT03613532 Phase I Busulfan + Fludarabine + Venetoclax Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN Recruiting
NCT03614728 Phase II Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Recruiting
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Not yet recruiting
NCT03722407 Phase II Ruxolitinib Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion Not yet recruiting
NCT03746041 Phase I Abaloparatide + Bevacizumab A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes Recruiting
NCT03770429 Phase I AZD6738 AZD6738 for Patients With Progressive MDS or CMML Not yet recruiting
NCT03807063 Phase I Rimiducid BPX-501 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting